News
Prescient (ASX: PTX) shares jump 6% on new US patent
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key US Patent for its OmniCAR portfolio “SpyCatcher and SpyTag: Universal…
News
Prescient (ASX: PTX) rolls out new cell therapy platform, CellPryme-M
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell therapy platform, “CellPryme-M”. It is a high-performance cell therapy manufacturing…
News
Prescient (ASX: PTX) expands its PTX-200 trial in AML patients
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing its study of diseases of unmet medical needs. PTX will…